Despite these data, the use of immunotherapy in a patient with BRAF wild-type melanoma and, more specifically, the use of combined CTLA-4 and PD-1 checkpoint-inhibition therapy with recurrent resectable melanoma is a rational therapeutic choice. Here, CTLA4 is linked to melanoma.